Protease-Activated Biosensors for Pathogen Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for rapidly diagnosing and treating bacterial infections are hindered by the complexity of microbial communities, leading to lengthy diagnostic processes and the emergence of antibiotic-resistant bacteria due to broad-spectrum antibiotics, which also harm beneficial microbes, causing chronic illnesses.
Innovation Solution
Development of a construct comprising a pathogenic bacterium protease propeptide conjugated to a detectable label, allowing for specific detection and potential killing of pathogenic bacteria by exploiting the native enzymatic machinery of the bacteria, using proteases as biomarkers and activators for biosensors and antimicrobials.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad-spectrum antibiotics are used to eliminate pathogenic bacteria, then bacterial infections are treated, but beneficial microbes are harmed and antibiotic-resistant bacteria emerge
Solution Approach 1:
The patent exploits the pathogenic bacteria's own protease enzymes (harmful factors) as biomarkers and activators for biosensors and antimicrobials. By converting the bacteria's enzymatic machinery into a detection and targeting mechanism, the system achieves selective elimination of pathogens while preserving beneficial microbes, thus resolving the contradiction between effective treatment and harm to beneficial organisms.
Solution Approach 2:
The patent introduces protease-specific constructs as intermediaries that mediate between the pathogenic bacteria and the therapeutic response. These constructs include protease-activated biosensors and protease-targeted antimicrobials that selectively recognize and respond to pathogenic bacteria through their unique protease enzymes, enabling precise treatment without broad-spectrum effects.
2Measurement precision
If lengthy sample processing and culture methods are used to distinguish pathogens from microbiota, then detection accuracy is improved, but diagnostic time increases
Solution Approach 1:
The patent replaces complex mechanical culture methods with protease-activated biosensors that use optical, fluorescent, or other non-mechanical detection mechanisms. These biosensors directly detect pathogenic bacteria through their protease enzymes in clinical samples without requiring lengthy culture processes, thereby maintaining high detection accuracy while dramatically reducing diagnostic time.
Solution Approach 2:
The patent employs protease-activated biosensors that utilize the pathogenic bacteria's own protease enzymes to trigger the detection signal. The biosensors are designed to be activated specifically by pathogenic proteases, allowing the pathogens to essentially mark themselves for detection without requiring external processing or culture steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid and specific detection of pathogenic bacteria and targeted elimination within complex microbial communities, reducing the risk of harming non-pathogenic bacteria and promoting antibiotic resistance.
Implementation Method 1
the bacterium produces the protease that binds to the propeptide, and monitoring a detectable signal for the label before and after the contacting, whereby a qualitative and/or quantitative change in the detectable signal upon contacting indicates that the pathogenic bacterium is present in the sample
Data Source
AI summary
The present disclosure relates, in one aspect, to the unexpected discovery that the native enzymatic machinery of pathogenic bacteria can be harnessed to develop biosensors and antimicrobials that target disease-causing microbes in the gut. The present approach relates in one aspect to the use of proteases for the design of these precision tools.